Drugs / IUAb190708
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07584954 | Jun 2024 → Jun 2028 expected | — | Jun Zhou | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IUAb190708 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07584954 ↗ |
| Modality | Monoclonal antibody | “IUAb190708 is a humanized monoclonal immunoglobulin G1 κ subclass (IgG1) antibody” NCT07584954 ↗ |
| Route | Intravenous | “eligible subjects will be administered with IUAb190708 at different doses via intravenous infusion” NCT07584954 ↗ |
| Target | CD274 | “IUAb190708 is a humanized monoclonal immunoglobulin G1 κ subclass (IgG1) antibody that specifically recognizes PD-L1 (also known as CD274)” NCT07584954 ↗ |